Warning: mkdir(): Permission denied in /home/virtual/lib/view_data.php on line 81
Warning: fopen(upload/ip_log/ip_log_2024-05.txt): failed to open stream: No such file or directory in /home/virtual/lib/view_data.php on line 83
Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 Prophylactic effects of trimethoprim-sulfamethoxazole in Toxoplasma-infected mice
Prophylactic effects of trimethoprim-sulfamethoxazole in Toxoplasma-infected mice
Y H Lee,*D Y Lee and DW Shin
Department of Parasitology, College of Medicine, Chungnam National University, Daejeon 301-131, Korea.
Received October 02, 1993; Accepted October 26, 1993.
Abstract
This study was performed to evaluate the prophylactic effects of trimethoprim-sulfamethoxazole (TMP-SMZ) in mice experimentally infected with virulent RH strain and avirulent Beverley strain of T. gondii. The mice infected with 1 × 105 tachyzoites were used in the measurement of mean survival days, and the mice infected with 10 cysts were used in the titrations of specific antibodies and enumeration of brain cysts. Mean survival days of mice were significantly increased in mice treated with TMP-SMZ as compared with spiramycin-treated and untreated control group. Mean survival days and survival rates of mice were increased according to the increment of dosages, and TMP-SMZ protected 100% of mice after fifteen daily dose of 24 mg/mouse or more administered orally. Toxoplasma-specific serum IgG and IgM antibody titers were significantly lower in mice treated with TMP-SMZ than those of spiramycin-treated and untreated control group. Toxoplasma cysts were not found in mice treated with TMP-SMZ at a dose of 24 mg/mouse or more per day, but the group of spiramycin treatment and untreated controls were found in the brain from 20 days after infection. The present results revealed that TMP-SMZ can be used as a prophylactic agent against murine toxoplasmosis after intraperitoneally challenges with the virulent or avirulent strain of T. gondii.
Figures
Fig. 1 Survial rates of mice infected imtraperitoneally with 1 × 105 tachyzoites of T. gondii. There were 10 mice in each group. Symbol: ○, infected control; •, group 1; ▿, group 2; ▾, group 3; □, group 4; ▪, group 5.
Fig. 2 /serum IgG antibody titers of mice infected intraperitoneally with 10 cycts fo T. gondii. The results are expressed as mean of 5 mice.
Fig. 3 Serum IgG antibody titers of mice infected intraperitomeally with 10 cysts of T. gondii. The results are expressed as mean of 5 mice.
Figs. 4-5 Fig. 4.Toxoplasma cysts in the mouse brain parenchyma by PAP method. Bar equals 20 µm. Fig. 5.Toxoplasma cyst purified by density-gradient centrifugation on Percoll. Bar equals 20 µm.
Tables
Table 1 Mean survival days of mice infected intraperitoneally with 1 × 105 tachyzoites of T. gondii
Table 2 No. of cysts identified by peroxidase anti-peroxidase method in the brain of mice infected inrtaperitoneally with 10 cysts of T. gondii
Table 3 No. of cysts purified by density-gradient centrifugation on Percoll in mice infected intraperitoneally with 10 cysts of T. gondii
References
1.
Brinkmann V, Remington JS, Sharma SD. Protective immunity in toxoplasmosis: correlation between antibody response, brain cyst formation, T-cell activation, and survival in normal and B-cell-deficient mice bearing the H-2k haplotype. Infect Immun 1987;55(4):990–994.
2.
Canessa A, Del Bono V, De Leo P, Piersantelli N, Terragna A. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis 1992;11(2):125–130.
3.
Carr A, Tindall B, Brew BJ, Marriott DJ, Harkness JL, Penny R, Cooper DA. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117(2):106–111.
4.
Chang HR, Pechere JC. Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection. J Antimicrob Chemother 1988;22 Suppl B:87–92.
5.
Choi JS, et al. Yonsei Rep Trop Med 1980;11:39–42.
6.
Choi WY. Diagnosis and epidemiology of toxoplasmosis in Korea. Korean J Parasitol 1990;28 Suppl:41–44.
7.
Cornelissen AW, Overdulve JP, Hoenderboom JM. Separation of Isospora (Toxoplasma) gondii cysts and cystozoites from mouse brain tissue by continuous density-gradient centrifugation. Parasitology 1981;83(Pt 1):103–108.
8.
Grossman PL, Remington JS. The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg 1979;28(3):445–455.
9.
Haverkos HW. Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med 1987;82(5):907–914.
10.
Lainson R. Observations on the development and nature of pseudocysts and cysts of Toxoplasma gondii. Trans R Soc Trop Med Hyg 1958;52(5):396–407.
13.
McCabe RE, Luft BJ, Remington JS. The effects of cyclosporine on Toxoplasma gondii in vivo and in vitro. Transplantation 1986;41(5):611–615.
14.
Nguyen BT, Stadtsbaeder S. Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice. Br J Pharmacol 1983;79(4):923–928.
15.
Norrby R, Eilard T, Svedhem A, Lycke E. Treatment of toxoplasmosis with trimethoprim-sulphamethoxazole. Scand J Infect Dis 1975;7(1):72–75.
16.
Rubin RH, Swartz MN. Trimethoprim-sulfamethoxazole. N Engl J Med 1980;303(8):426–432.
17.
Thiermann E, Apt W, Atias A, Lorca M, Olguin J. A comparative study of some combined treatment regimens in acute toxoplasmosis in mice. Am J Trop Med Hyg 1978;27(4):747–750.
18.
Voller A, Bidwell DE, Bartlett A. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bull World Health Organ 1976;53(1):55–65.
PDF Links
Full text via DOI
Download Citation 
